Immunotherapy for Cancer
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
750
NCT05232916
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Phase: Phase 3
Role: Lead Sponsor
Start: Aug 11, 2022
Completion: Dec 31, 2026
Loading map...